{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-056920","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.605809+00:00","generated_at":"2026-06-15T12:33:31.572882+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ProMIS Neurosciences receives FDA IND clearance for Alzheimer's antibody PMN310","bullets":["FDA cleared IND for PMN310, a monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease.","Preclinical data showed PMN310's selective binding to toxic oligomers with minimal plaque binding, potentially reducing ARIA risk.","Company plans to initiate Phase 1a trial to evaluate pharmacokinetics, safety, and tolerability in healthy volunteers.","CEO Gail Farfel called the clearance an important corporate milestone toward a next-generation AD therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-056920","json":"https://secwatch.observer/filing/0001104659-23-056920.json","markdown":"https://secwatch.observer/filing/0001104659-23-056920.md","text":"https://secwatch.observer/filing/0001104659-23-056920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000110465923056920/0001104659-23-056920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000110465923056920/tm2314972d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:33:31.572882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}